Compromised antigen presentation ranks among the top mechanisms that render cancers non-immunogenic (non-responsive to immune ...

GEO-CM04S1 Demonstrates Durable T Cell and Antibody Responses in Healthy and Immunocompromised Populations ...

today recapped the successful presentation of new clinical data on its multi-antigen SARS-CoV-2 vaccine candidate, GEO-CM04S1, delivered at the 25th Annual World Vaccine Congress in Washington ...

May 1, 2025GeoVax Labs, Inc. beats earnings expectations. Reported EPS is $-0.45, expectations were $-0.59. Operator: Good afternoon. And welcome everyone to the GeoVax First Quarter 2025 Corporate ...

Topas Therapeutics today announced that it will present clinical Phase 2a data on its lead candidate, TPM502, in celiac ...

(NEPC). The findings enhance the understanding of the treatment of androgen receptor functions in NEPC. Neuroendocrine prostate cancer (NEPC) arises primarily through neuroendocrine ...